[Clinical description of effectiveness of pioglitazone in a complex therapy of patients with ischemic heart disease on background of metabolic syndrome].
The results suggest that addition of pioglitazone in a complex treatment therapy of patients with ischemic heart disease on background of metabolic syndrome was not associated with an increased ischemic heart disease (IHD) risk and improved the clinical course of IHD, increased effectiveness of standard therapy for patients with IHD and metabolic syndrome.